keyword
MENU ▼
Read by QxMD icon Read
search

Denosumab

keyword
https://www.readbyqxmd.com/read/28921820/systematic-review-and-network-meta-analysis-on-the-relative-efficacy-of-osteoporotic-medications-men-with-prostate-cancer-on-continuous-androgen-deprivation-therapy%C3%A2-to-reduce-risk-of-fragility-fractures
#1
REVIEW
Yeesha Poon, Petros Pechlivanoglou, Shabbir M H Alibhai, David Naimark, Jeffrey S Hoch, Emmanuel Papadimitropoulos, Mary-Ellen Hogan, Murray Krahn
BACKGROUND: Androgen deprivation therapy (ADT) is an effective treatment for men with advanced prostate cancer, but loss of bone mineral density (BMD) is a major risk factor for fractures. This analysis evaluated the relative effectiveness of osteoporosis treatments using BMD as a surrogate endpoint for fragility fractures in men on continuous ADT. METHOD: We included randomized controlled trials studying bisphosphonates, denosumab, toremifene, and raloxifene in patients with non-metastatic prostate cancer on ADT for review...
September 18, 2017: BJU International
https://www.readbyqxmd.com/read/28920136/jaw-pain-in-a-pemphigus-patient-on-prednisolone-mycophenolate-mofetil-and-denosumab
#2
Pei Ming Yeo, Chia Chun Ang
No abstract text is available yet for this article.
August 2017: Annals of the Academy of Medicine, Singapore
https://www.readbyqxmd.com/read/28912972/denosumab-for-male-hemodialysis-patients-with-low-bone-mineral-density-a-case-control-study
#3
Hiroya Takami, Kazunori Washio, Hiromichi Gotoh
Denosumab increases bone mineral density (BMD) in patients not receiving hemodialysis therapy. However, limited data are available in the literature concerning the use of denosumab in hemodialysis patients. We treated male hemodialysis patients with low radius BMD with denosumab therapy for 1 year and evaluated its effect on radius BMD. Seventeen patients were treated with denosumab 60 mg every 6 months, and 20 patients were not treated with denosumab (control group). At seven days, the mean corrected calcium level decreased from 9...
2017: International Journal of Nephrology
https://www.readbyqxmd.com/read/28905737/giant-cell-tumor-of-bone-revisited
#4
Andreas F Mavrogenis, Vasileios G Igoumenou, Panayiotis D Megaloikonomos, Georgios N Panagopoulos, Panayiotis J Papagelopoulos, Panayotis N Soucacos
Giant cell tumor (GCT) of bone is a locally aggressive benign neoplasm that is associated with a large biological spectrum ranging from latent benign to highly recurrent and occasionally metastatic malignant bone tumor. It accounts for 4-10% of all bone tumors and typically affects the meta-epiphyseal region of long bones of young adults. The most common site involved is the distal femur, followed by the distal radius, sacrum, and proximal humerus. Clinical symptoms are nonspecific and may include local pain, swelling, and limited range of motion of the adjacent joint...
2017: SICOT-J
https://www.readbyqxmd.com/read/28890137/secular-trends-of-use-of-anti-osteoporosis-treatments-in-spain-a-population-based-cohort-study-including-over-1-5million-people-and-more-than-12years-of-follow-up
#5
Elisa Martín-Merino, Consuelo Huerta-Álvarez, Daniel Prieto-Alhambra, Arturo Álvarez-Gutiérrez, Dolores Montero-Corominas
OBJECTIVE: Different regulatory actions for anti-osteoporosis medication (AOM) were taken during the last years, including marketing of new drugs, safety warnings, or restrictions on the indications. We aimed to characterise the secular trends of AOM use in Spain from 2001 to 2013. METHODS: A cohort study using the Spanish Database for Pharmacoepidemiological Research in Primary Care (BIFAP), was performed. BIFAP includes anonym records for 4million patients. Participants entered the study when aged ≥50years in 2001-2013 and after 1year of data available, and were followed to an AOM prescription (including alendronate, other bisphosphonates, SERM (selective estrogen receptor modulators), strontium ranelate, teriparatide or denosumab), death, lost or the end of December 2013...
September 7, 2017: Bone
https://www.readbyqxmd.com/read/28885764/porphyrin-derivatives-inhibit-the-interaction-between-receptor-activator-of-nf-%C3%AE%C2%BAb-and-its-ligand
#6
Melanie Chypre, Maria-Bernadette Madel, Olivier Chaloin, Chlaudine Blin-Wakkach, Christophe Morice, Christopher G Mueller
Receptor Activator of NF-κB (RANK), a member of the TNF-receptor superfamily, plays an important role in bone resorption and stimulates immune and epithelial cell activation. Denosumab, a human monoclonal antibody blocking RANK ligand (RANKL), is approved for the treatment of osteoporosis and bone metastasis. However, a small molecule inhibiting RANK-RANKL interaction would be beneficial to reduce costs and to facilitate treatments with orally available therapeutic agents. Here, we report the discovery of the first non-peptidic inhibitors of RANK-RANKL interactions...
September 8, 2017: ChemMedChem
https://www.readbyqxmd.com/read/28883763/cyberknife-stereotactic-radiosurgery-and-denosumab-for-giant-cell-tumour-of-the-skull-base-case-report
#7
Cuauhtemoc de la Peña, Jorge H Guajardo, Maria F Gonzalez, Miguel A Hinojosa, Erick Cardona
Giant cell tumours (GCT) of the skull is a rare entity with only small number of cases reported in literature and optimal treatment is yet to be determined. These tumours have shown high recurrence rates after incomplete surgery, usually occurring during the first year. Even with new surgical techniques a complete resection in skull base tumours is not always possible without functional compromise. Therefore, adjuvant therapy is essential to enhance local control and quality of life. We report a rare case of a 34-year-old male with giant cell tumour (GCT) of the skull base involving the petrous bone, clivus and sphenoid body...
November 2017: Reports of Practical Oncology and Radiotherapy
https://www.readbyqxmd.com/read/28880683/rankl-a-therapeutic-target-for-bone-destruction-in-rheumatoid-arthritis
#8
Sakae Tanaka, Yoshiya Tanaka, Naoki Ishiguro, Hisashi Yamanaka, Tsutomu Takeuchi
Rheumatoid arthritis (RA) is a chronic inflammatory disorder characterized by progressive joint destruction. Recent studies have indicated the critical involvement of osteoclasts in bone destruction in RA. The osteoclast differentiation factor receptor activator of NF-κB ligand (RANKL), which belongs to the tumor necrosis factor-α superfamily, plays a critical role in osteoclast differentiation and bone destruction in RA. Denosumab, an antibody against human RANKL, efficiently suppressed the progression of bone erosion in RA patients in a randomized controlled study, and is considered as a putative therapeutic option for preventing bone destruction in RA...
September 7, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/28874892/treatment-patterns-and-trends-in-patients-dying-of-prostate-cancer-in-quebec-a-population-based-study
#9
A Dragomir, J Rocha, M Vanhuyse, F L Cury, W Kassouf, J Hu, A G Aprikian
INTRODUCTION: Since just after the year 2000 in Quebec, the management of metastatic castration-resistant prostate cancer (mcrpc) has evolved considerably, with the inclusion of docetaxel-based chemotherapy, bone-targeted therapies (zoledronic acid and denosumab), and more recently, abiraterone, enzalutamide, and cabazitaxel for docetaxel-refractory patients. In the present study, we aimed to analyze contemporary mcrpc management patterns and therapy utilization trends in Quebec. METHODS: The study cohort consisted of patients dying of prostate cancer (pca) between January 2001 and December 2013, selected from Quebec public health care insurance databases...
August 2017: Current Oncology
https://www.readbyqxmd.com/read/28871570/osteoporosis-drug-treatment-duration-and-management-after-discontinuation-a-position-statement-from-the-svgo-asco
#10
Christian Meier, Brigitte Uebelhart, Bérengère Aubry-Rozier, Martin Birkhäuser, Heike A Bischoff-Ferrari, Diana Frey, Reto W Kressig, Olivier Lamy, Kurt Lippuner, Petra Stute, Norbert Suhm, Serge Ferrari
Antiosteoporotic drugs are recommended in patients with fragility fractures and in patients considered to be at high fracture risk on the basis of clinical risk factors and/or low bone mineral density. As first-line treatment most patients are started with an antiresorptive treatment, i.e. drugs that inhibit osteoclast development and/or function (bisphosphonates, denosumab, oestrogens or selective oestrogen receptor modulators). In the balance between benefits and risks of antiresorptive treatment, uncertainties remain regarding the optimal treatment duration and the management of patients after drug discontinuation...
September 5, 2017: Swiss Medical Weekly
https://www.readbyqxmd.com/read/28867727/influence-of-japanese-regulatory-action-on-denosumab-related-hypocalcemia-using-japanese-adverse-drug-event-report-database
#11
Mayu Takeyama, Kimie Sai, Takuya Imatoh, Katsunori Segawa, Noriyasu Hirasawa, Yoshiro Saito
The anti-receptor activator of nuclear factor kappa-B ligand (RANKL) antibody, Denosumab (DEN), was approved in April 2012 in Japan, but a Dear Healthcare Professional Letter of Rapid Safety Communication was released in September, 2012 by the regulatory authority because of the severe hypocalcemia risks. Currently, the effectiveness of this regulatory action has not been evaluated and, therefore, this study aimed to assess its impact on DEN-induced hypocalcemia using the Japanese Adverse Drug Event Report database (JADER)...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28863882/evaluation-of-mandibular-bone-after-dental-extraction-in-rats-treated-with-antiresorptive-drugs
#12
Victor Lousan Do Nascimento Poubel, Diogo Lenzi Capella, Adair Roberto Soares Santos, Márcio Correa, Letícia Ruhland Correa, Elena Riet Correa Rivero
PURPOSE: Zoledronic acid (ZOL) and denosumab (Dmab) are commonly used to treat bone pathologies. Because these drugs suppress bone metabolism, this study sought to compare their effect on bone repair after tooth extraction. MATERIALS AND METHODS: Four-week-old male Wistar rats were randomly assigned to 1 of 3 groups: ZOL 0.125 mg/kg, Dmab 0.25 mg/kg, or saline solution 10 mL/kg (control). After 1 week of treatment, the first left molar was extracted; the rats were euthanized at 28 days...
August 3, 2017: Journal of Oral and Maxillofacial Surgery
https://www.readbyqxmd.com/read/28857847/advances-in-treatment-of-glucocorticoid-induced-osteoporosis
#13
Emory Hsu, Mark Nanes
PURPOSE OF REVIEW: The aim of this study is to summarize monitoring, prevention and treatment options of glucocorticoid-induced osteoporosis for patients on chronic glucocorticoid therapy. RECENT FINDINGS: Recent meta-analyses highlight the efficacy of bisphosphonate use in improving bone mineral density and in reducing vertebral fractures in the setting of long-term glucocorticoid use. A new study has now shown that alendronate also reduces the risk of hip fracture in glucocorticoid use...
August 28, 2017: Current Opinion in Endocrinology, Diabetes, and Obesity
https://www.readbyqxmd.com/read/28856360/postpartum-treatment-of-metastatic-recurrent-giant-cell-tumor-of-capitate-bone-of-wrist
#14
Robert L Satcher, Vinod Ravi, Wei-Lien Wang, Scott Oates
Giant cell tumors (GCTs) are aggressive benign lesions that occur in the bone epiphysis. They are most often found in the long bones of the lower extremities. Wrist bone involvement is rare, capitate bone involvement exceedingly rare. Treatment in the wrist usually consists of excision, local adjuvant treatment, and cementing and/or bone grafting. GCTs also metastasize to the lungs; pulmonary lesions are excised and systemic therapy provided. We present the case of a 19-year-old woman with GCT of the capitate bone...
July 2017: American Journal of Orthopedics
https://www.readbyqxmd.com/read/28844196/atypical-femoral-fracture-associated-with-bone-modifying-agent-for-bone-metastasis-of-breast-cancer-a-report-of-two-cases
#15
Daisuke Tateiwa, Hidetatsu Outani, Saya Iwasa, Yoshinori Imura, Takaaki Tanaka, Kazuya Oshima, Norifumi Naka, Nobuhito Araki
Atypical femoral fractures (AFFs) are recently observed as a complication of long-term bone-modifying agent (BMA; bisphosphonate or denosumab) therapy for bone metastases. We describe the cases of two women diagnosed with breast cancer who developed incomplete AFF associated with BMAs prescribed for bone metastases. Radiographs of their femurs revealed thickening of the lateral subtrochanteric cortex, and tomosynthesis revealed a visible fracture line in the thickened cortex. They were initially treated with conservative management; however, the incomplete fracture resulted in a complete fracture...
September 2017: Journal of Orthopaedic Surgery
https://www.readbyqxmd.com/read/28838807/skeletal-health-in-breast-cancer-survivors
#16
REVIEW
Olivier Bruyère, Pierre Bergmann, Etienne Cavalier, Evelien Gielen, Stefan Goemaere, Jean-Marc Kaufman, Serge Rozenberg, Jean-Jacques Body
Although some risk factors for breast cancer might be protective for osteoporosis, several cross-sectional studies have reported, nevertheless, that patients with breast cancer have a lower bone mass and potentially a higher incidence of fractures than expected. In any case, it appears that patients with breast cancer are not protected from osteoporosis, which provides further support for the recommendation that bone health is assessed after a diagnosis of breast cancer. Most adjuvant therapies will lead to increased bone loss and a higher fracture rate...
August 18, 2017: Maturitas
https://www.readbyqxmd.com/read/28835672/osteoporosis-discontinuing-denosumab-discouraged
#17
Joanna Collison
No abstract text is available yet for this article.
August 24, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28828294/a-review-of-the-mechanism-of-action-and-clinical-applications-of-sorafenib-in-advanced-osteosarcoma
#18
James Coventon
OBJECTIVE: To summarise the contemporary literature regarding sorafenib and its effectiveness as a novel treatment in advanced osteosarcoma. BACKGROUND: Modern treatment has seen the cure rate of osteosarcoma increase to 65%. However, in patients who do not achieve remission, prognosis is poor, as there are no effective, consensual second line therapies. Sorafenib has emerged as a potentially viable drug to be used in this context. METHOD: A literature review was conducted evaluating articles pertaining to osteosarcoma and sorafenib...
September 2017: Journal of Bone Oncology
https://www.readbyqxmd.com/read/28816971/combining-of-serial-embolization-and-denosumab-for-large-sacropelvic-giant-cell-tumor-case-report-of-3-cases
#19
Tao Ji, Yi Yang, Yifei Wang, Kunkun Sun, Wei Guo
RATIONALE: Both serial arterial embolization (SAE) and denosumab have been proved to be effective in treatment for giant cell tumor (GCT). There is potential synergic effect of combining two methods. The purpose of current study is to justify a new treatment strategy of combination of SAE and denosumab as neoadjuvant or stand-alone treatment for large sacropelvic giant cell tumor. PATIENT CONCERNS: Pelvic and sacral GCTs tend to be very large size and vascular. The concerns of surgical treatment were invasiveness of extensive surgery, intraoperative hemorrhage, nerve function jeopardized and local recurrence...
August 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28805705/changes-of-bone-related-minerals-during-denosumab-administration-in-post-menopausal-osteoporotic-patients
#20
Takako Suzuki, Yukio Nakamura, Hiroyuki Kato
OBJECTIVES: This retrospective study included 21 patients with primary osteoporosis who were treated with the anti-resorption drug, denosumab. To date, there has been no detailed report on the changes of bone-related minerals after anti-resorption drug therapy. METHODS: Twenty-one post-menopausal females were retrospectively enrolled. Serum zinc (Zn), magnesium (Mg), iron (Fe), copper (Cu), grip strength, and estimated glomerular filtration rate (eGFR) were examined at one week and 1, 2, 4, 6, 8, 10, and 12 months...
August 13, 2017: Nutrients
keyword
keyword
8329
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"